Israel Aerospace Industries Ltd. (IAI) (TASE: ARSP.B1) subsidiary Elta Systems has won two multiyear contracts worth $280 million altogether to supply radar systems to the Republic of Korea Army.
IAI's usual policy is to receive a down payment of 25-35% on contracts, suggesting that it will record $70-98 million revenue from the contracts in its consolidated financial report for 2009.
In the first contract, Elta will supply its EL/M2032 fire control radar systems for combat aircraft, for South Korea's indigenous TA/FA 50 Golden Eagle jet. The system improves the jet's air-to-air, air-to-ground, and air-to-sea combat capabilities. The system can identify and classify a range of targets at long ranges, provide high-resolution combat arena maps, and has additional applications as well. The Golden Eagle trainer and light attack strike fighter is a joint development of KAI / Lockheed Martin and Lockheed Martin Co. (NYSE: LMT). The radars will be jointly manufactured with South Korean sensors and communications equipment maker LIG Nex1 Ltd.
In the second contract, Elta will supply its advanced radar system for air defense, which is slated to become operational by the South Korean Army in 2012.
Dr. Alon Monsonego , a researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients. This continuing research at Ben-Gurion University of the Negev could one day lead to specific Alzheimer's vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.
Amyloid beta-peptide accumulates in the brain of AD patients where it appears to promote neuronal damage. In the article, recently published in the Journal of Immunology, BGU researcher Dr. Alon Monsonego determined that introducing A-beta into the brain triggers a natural immune response which can be detected in humans.
Importantly, the research team showed that the specificity and magnitude of this body response to A-beta depends on certain key genes of the immune system, which are highly polymorphic in the population (this means that except for identical twins, almost each of us has a different combination of genes termed "HLA alleles").
Furthermore, this research took an unusual approach combining humans and humanized mouse models. "We began with characterizing the genes in humans in a collaboration with the laboratories of Dr. Weiner and Dr. Selkoe at Harvard then did the same study in mice using a mouse model of multiple sclerosis with the laboratory of Dr. Altmann- Imperial College School of Medicine, UK," Monsonego explains. "We then generated a humanized mouse model of AD, with a specific gene that was present in approximately 30 percent of our study group (HLA DR15 allele). Conceivably, those people that have this gene could receive the same vaccine which will teach a person's immune system to better fight the disease."
Monsonego continues, "As in other mouse models of the disease, we show that with aging A-beta aggregates accumulate in brain areas of cognitive functions and stimulate an inflammatory reaction in the brain. However, stimulating an immune response to A-beta in these humanized mice not only resulted in a highly efficient clearance of A-beta (plaque) from the brain, but also in a markedly reduced inflammatory reaction. Furthermore, we were able to predict that the characteristics of immune response in mice were the same as in the humans.
"This study thus provides the basis for developing an individual-based (personalized medicine) immunotherapeutic approach to Alzheimer's disease since different populations will respond differently to a vaccine based on their genetic background," Monsonego explains. "Now that we've proven we can anticipate the specific responses for several abundant genes in the population, further study is needed to ensure safety and efficacy in our humanized mouse model of AD."